drugset / Trial / NCT05576623
Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The safety and immunogenicity of AdCLD-CoV19-1 OMI (5.0x10\^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated.
Timeline
- Start
- 2022-09-14
- Primary completion
- 2023-03-10
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AdCLD-CoV19-1 OMI | Vaccine | 5e+10 unknown | Intramuscular |